The drug hypersensitivity syndrome: What is the pathogenesis?

Archives of Dermatology

Volumn 137, Issue 3, 2001, Pages 357-364

  Sullivan, J R ^a   Shear, N H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANAPHYLAXIS; ARTICLE; DRUG HYPERSENSITIVITY; FEVER; IATROGENIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RASH; VIRUS INFECTION;

DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS; SYNDROME; VIRUS DISEASES;

EID: 0035068362     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Anticonvulsant hypersensitivity syndrome: In vitro assessment of risk
2. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms
3. Mechanisms of drug reactions: The metabolic track
4. Lamotrigine-associated anticonvulsant hypersensitivity syndrome
5. Kawasaki-like syndrome caused by carbamazepine
6. Multisystem hypersensitivity reaction to lamotrigine
7. DIDMOHS: A proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome
8. DIDMOHS: A proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome
9. What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?
10. Drug-induced pseudolymphoma and hypersensitivity syndrome
11. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management
12. Azathioprine hypersensitivity-like reactions: A case report and a review of the literature
13. Colitis may be part of the antiepileptic drug hypersensitivity syndrome
14. A clinical study of minocycline-induced pneumonitis
15. Increased in vitro production of interleukin 6 in response to trimethoprim among persons with trimethoprim-induced systemic adverse reactions
16. Classification of allergic reactions responsible for clinical hypersensitivity and disease
17. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism
18. New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system
19. In vivo and in vitro testing for adverse drug reactions
20. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
21. Pathophysiology of drug-elicited exanthems
22. Drug-protein conjugation and its immunological consequences
23. Lamotrigine-specific lymphocyte reactivity: Possible role in cutaneous reactions
24. Evidence for reactive drug metabolites in lamotrigine-associated drug hypersensitivity syndrome
25. Factors influencing the incidence of lamotrigine-related skin rash
26. The tolerability of lamotrigine in children
27. Safety review of adult clinical trial experience with lamotrigine
28. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management
29. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency
30. Allergies to multiple antiseizure medications: A relationship to ANA and SSA
31. Cross sensitivity of skin rashes with antiepileptic drugs
32. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
33. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
34. Metabolic predisposition to cutaneous adverse drug reactions
35. Activation of pharmacological agents to radical intermediates
36. Immunologic mechanisms of penicillin allergy: A haptenic model for the study of allergy diseases in man
37. Drug disposition and drug hypersensitivity
38. Tolerance, danger, and the extended family
39. Carbamazepine-induced pneumonitis
40. Acute pulmonary hypersensitivity to carbamazepine
41. Role of viral infections in the induction of adverse drug reactions
42. Possible role of reactive oxygen species in antiviral defense
43. Free radicals in viral pathogenesis: Molecular mechanisms involving superoxide and NO
44. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome
45. Toxicity of sulphonamide reactive metabolites in HIV-infected and non-infected cells
46. IgM and IgG antibody levels to ampicillin in patients with infectious mononucleosis
47. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis
48. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity
49. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity
50. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs
51. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins
52. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions
53. H2 and more
54. H2 subsets: Paradigms lost?
55. Type 1 and type 2: A fundamental dichotomy for all T-cell subsets
56. Functional diversity of helper T lymphocytes
57. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome
58. Interleukin-5 and allergic inflammation
59. An inflammatory eruption associated with recombinant human IL-6
60. Lymphocyte activation in cutaneous drug reactions
61. Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides
62. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection
63. Fas ligand in human serum
64. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
65. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
66. Tumor necrosis factor receptor and Fas signaling mechanisms
67. Genetic control of interleukin 12 responsiveness: Implications for disease pathogenesis
68. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
69. H2 switch is a critical step in the etiology of HIV infection
70. Dissociation of xanthine oxidase induction and cytochrome P450 depression during interferon induction in the rat
71. Fundamental of clinical methodology, II: Etiology
72. Encephalopathy and fatty degeneration of the viscera: A disease entity in childhood
73. Inborn errors of metabolism in children referred with Reye's syndrome: A changing pattern
74. Reye's syndrome and aspirin: Evidence for a dose-response effect